| Identification | More | [Name]
L-XYLOSE | [CAS]
609-06-3 | [Synonyms]
L-XYL
L-(-)-XYLOSE
L-XYLOSE
XYLOSE
XYLOSE, L
L-(-)-Xylose, 99+%, mixture of anomers
L(-)XYLOSE 99%
L-Xylose (9CI)
L-Xylose,99%
l-(-)-xylose, mixture of anomers
XYLOSE, L-(RG) | [EINECS(EC#)]
210-174-1 | [Molecular Formula]
C5H10O5 | [MDL Number]
MFCD00151096 | [Molecular Weight]
150.13 | [MOL File]
609-06-3.mol |
| Chemical Properties | Back Directory | [Appearance]
WHITE FINE CRYSTALLINE POWDER | [Melting point ]
150-152 °C(lit.)
| [Boiling point ]
191.65°C (rough estimate) | [density ]
1.525 | [refractive index ]
-20 ° (C=10, H2O) | [storage temp. ]
Keep in dark place,Sealed in dry,Room Temperature | [solubility ]
H2O: 0.1 g/mL, clear, colorless
| [form ]
Crystalline Powder | [pka]
12.46±0.20(Predicted) | [color ]
White to off-white | [Optical Rotation]
[α]24/D 18.7°, c = 4 in H2O | [Water Solubility ]
within almost transparency | [Sensitive ]
Hygroscopic | [BRN ]
1723080 | [InChIKey]
SRBFZHDQGSBBOR-VVZXFQNISA-N | [LogP]
-2.390 (est) | [CAS DataBase Reference]
609-06-3(CAS DataBase Reference) | [EPA Substance Registry System]
L-Xylose (609-06-3) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S24/25:Avoid contact with skin and eyes .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [WGK Germany ]
3
| [F ]
3-10 | [TSCA ]
Yes | [HS Code ]
29400090 |
| Hazard Information | Back Directory | [Chemical Properties]
WHITE FINE CRYSTALLINE POWDER | [Uses]
L-Xylose is used in the synthesis of L-Xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. | [Application]
l-Xylose is a suitable starting material for the production of L-ribonucleosides. L- Xylose can be converted into an L-ribose derivative via oxidation and reduction steps. This product is then glycosylated to give L-ribonucleosides: L-uridine, L-cytidine, L- adenosine and L-guanosine (Moyroud and Strazewski, 1999; Chelain et al., 1995).
L-Xylose can also be used as a starting material for the production of polyhydroxypyrrolidines and related analogues. These compounds have many biological activities. They are shown to have anti-HIV effects, inhibit tumor growth, and also act as ?- and ?-glucosidase inhibitors, which is of relevance for the development of diabetes drugs (Behr and Guillerm, 2007). | [Definition]
ChEBI: A xylose of ring-opened form having L-configuration. | [Preparation]
L-Xylose can be produced from L-xylulose by isomerization. This can be achieved either enzymatically or chemically under alkaline conditions. The equilibrium of the reaction between D-xylose and D-xylulose in an aqueous solution has been determined at pH 6.8-7.4 and at 25 °C to be 85:15 in favor of D-xylose (Tewari et al., 1985). | [Synthesis]
The general procedure for the synthesis of (2S,3R,4S)-2,3,4,5-tetrahydroxyvaleraldehyde from the compound (CAS:1195193-89-5) was as follows: compound 9 (10.0 g, 31.42 mmol) was dissolved in 30% sodium ethanol solution (22.7 g, 126.3 mmol). After the reaction solution was concentrated to 30 mL of dichloromethane, the mixture was stirred at 20-30 °C for 2-5 hours. After completion of the reaction, the pH was adjusted to 7 with 3N hydrochloric acid and the organic phase was separated. The aqueous phase was extracted three times with dichloromethane and the combined organic phases were dried with anhydrous sodium sulfate. After filtration to remove the solids, the organic phase was concentrated to give white crystals of L-xylose (4.4 g, 92% yield). | [References]
[1] Patent: CN108752396, 2018, A. Location in patent: Paragraph 0068-0070 |
|
|